FOR U.S. RESIDENTS ONLY

Carac® Home
About AKs
About Carac®
News
Links
Find a Dermatologist
Patient Information for Carac®

For HealthCare Professionals
Knock Out AKs with Carac®
Full Prescribing Information

For Health Care Professionals
colorbar

Efficacy | Convenience | Irritation Profile | Microsponge® Technology
An AK Contender | Full Prescribing Information


Microspheres

Microsponge® Technology

  • The only Microsponge®-entrapped 5-FU topical product

  • Carac® contains 0.5% fluorouracil, with 0.35% incorporated into a patented porous microsphere (Microsponge®)[5]

  • The Microsponge® particles are dispersed in a cream and hold the active ingredient until applied
    to the skin[9]

  • Unique formulation[5]

  • Cosmetically elegant

Microsponge® is a registered trademark of Cardinal Health, Inc. or one of its subsidiaries.

Carac® is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.

IMPORTANT SAFETY INFORMATION

Carac® is contraindicated in women who are or may become pregnant, in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency, and in patients with known hypersensitivity to any of its components. In clinical trials, the most common drug-related adverse event was application site reaction (94.6%), which included: erythema, dryness, burning, erosion, pain, and edema. Some patients also experienced eye irritation (5.4%), including stinging and burning.

For more information, please see Full Prescribing Information for Carac®
This site is intended for U.S. residents only. Full Prescribing Information for Carac®